Abstract
The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Reviews on Recent Clinical Trials
Title:Gut Microbiota and Alcoholic Liver Disease
Volume: 11 Issue: 3
Author(s): Emidio Scarpellini, Mariana Forlino, Marinella Lupo, Carlo Rasetti, Giammarco Fava, Ludovico Abenavoli and Adriano De Santis
Affiliation:
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Abstract: The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Export Options
About this article
Cite this article as:
Scarpellini Emidio, Forlino Mariana, Lupo Marinella, Rasetti Carlo, Fava Giammarco, Abenavoli Ludovico and De Santis Adriano, Gut Microbiota and Alcoholic Liver Disease, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160810100538
DOI https://dx.doi.org/10.2174/1574887111666160810100538 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Future Applications of Probiotics
Current Nutrition & Food Science Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy
Mini-Reviews in Medicinal Chemistry Features Identification for Phenotypic Classification Based on Genes and Gene Pairs
Current Bioinformatics Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Present Scenario of M-Cell Targeting Ligands for Oral Mucosal Immunization
Current Drug Targets Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design Serotonin and Human Cognitive Performance
Current Pharmaceutical Design Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Current Drug Targets Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Therapeutic Potential of Nitrate Esters of Commonly Used Drugs
Current Topics in Medicinal Chemistry Library of Synthetic Compounds Based on Pyrazole Unit: Design and Screening Against Breast and Colorectal Cancer
Letters in Drug Design & Discovery Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases
Current Stem Cell Research & Therapy Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Transient Expression of Recombinant sPDGFRα-Fc in CHO DG44 Cells using 50-mL Orbitally Shaking Disposable Bioreactors
Protein & Peptide Letters Mucosal Immunisation: Adjuvants and Delivery Systems
Current Drug Delivery